GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
1-Year Return
49.13%
This Quarter Return
+8.51%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$264M
AUM Growth
+$30.1M
(+13%)
Cap. Flow
+$16.9M
Cap. Flow
% of AUM
6.39%
Top 10 Holdings %
Top 10 Hldgs %
42.61%
Holding
61
New
24
Increased
14
Reduced
12
Closed
7
Top Buys
| 1 |
TG Therapeutics
TGTX
|
$16.5M |
| 2 |
Pfizer
PFE
|
$8.16M |
| 3 |
Johnson & Johnson
JNJ
|
$7.75M |
| 4 |
uniQure
QURE
|
$7.55M |
| 5 |
Akero Therapeutics
AKRO
|
$7.27M |
Top Sells
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$39.1M |
| 2 |
Invesco QQQ Trust
QQQ
|
$13.3M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$10.9M |
| 4 |
Apellis Pharmaceuticals
APLS
|
$8.93M |
| 5 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$6.69M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
BridgeBio Pharma
BBIO
$9.91B
| $415K | 0.12% |
+25,000
| New | +$415K |
|
52
Vanda Pharmaceuticals
VNDA
$274M
| $85K | 0.03% |
+12,500
| New | +$85K |
|
53
RAPT Therapeutics
RAPT
$211M
| – | – |
-15,625
| Closed | -$2.48M |
|
54
Spyre Therapeutics
SYRE
$1.03B
| – | – |
-32,000
| Closed | -$360K |
|
55
SPDR S&P Biotech ETF
XBI
$5.28B
| – | – |
0
| – | – |
|
|
SGEN
56
DELISTED
Seagen Inc. Common Stock
SGEN
| – | – |
-85,000
| Closed | -$10.9M |
|
|
PRVB
57
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| – | – |
-400,000
| Closed | -$4.23M |
|
58
Altimmune
ALT
$314M
| – | – |
0
| – | – |
|
|
BPMC
59
DELISTED
Blueprint Medicines
BPMC
| – | – |
-20,000
| Closed | -$876K |
|
60
Design Therapeutics
DSGN
$348M
| – | – |
-82,853
| Closed | -$850K |
|
|
61
Invesco QQQ Trust
QQQ
$368B
| – | – |
-50,000
| Closed | -$13.3M |
|